Biotech advancing function-first discovery of antibodies selects ENPICOM to cut weeks from antibody discovery workflows
ENPICOM today announced that Evolved Therapeutics, a biotechnology company developing innovative antibody discovery platforms and therapeutic antibody candidates, has selected the ENPICOM Platform to accelerate data-to-insight across its antibody discovery campaigns, including next-generation sequencing (NGS) data analysis and clone selection.
Evolved Therapeutics has developed a patented, ultra-high-throughput, function-first discovery method for identifying rare monospecific, bispecific, and multispecific antibodies with unique functional profiles. The company is well-positioned to lead in the rapidly growing antibody market, with a platform designed to address a broad range of diseases and high-impact unmet patient needs. Central to that ambition is a high-performance digital infrastructure capable of keeping pace with the company's experimental throughput.
“We have ambitious R&D goals at Evolved, and a high-performance analysis tool is essential to achieving them,” said Brandon Clavette, VP Research & Development at Evolved Therapeutics. “We selected ENPICOM because it's built specifically for antibody discovery. It takes the data handling layer that would normally require dedicated bioinformatics capacity off our scientists' plates. Once data is ready for discovery, it's all there in ready-to-use tools, so no time is lost to manual transfers or processing.”
“We are honored to support innovative teams like Evolved Therapeutics,” said Nicola Bonzanni, Founder and CEO at ENPICOM. “Our goal with the ENPICOM Platform was to remove the bottleneck between antibody data and candidate selection. Researchers can take NGS, Sanger, or single B cell sequencing data through to a shortlist of developable candidates without writing code or routing requests through a bioinformatics team. With standard processes in place, work that previously took weeks of data handling can be done in a day.”
Function-first antibody discovery, especially when paired with NGS, generates large volumes of data that must be processed, clustered, and analyzed before candidates can be selected for follow-up assays. In most discovery programs, that step relies on custom analysis pipelines and dedicated bioinformatics support, a dependency that routinely adds weeks per campaign and absorbs a meaningful share of scientific staff time on pipeline setup, format reconciliation, and one-off requests. For smaller teams in particular, it can mean carrying additional bioinformatics headcount that would otherwise be spent on science.
The ENPICOM Platform integrates sequence and experimental assay data, supporting clustering, phylogenetic and enrichment analyses, and exposed liability annotation in a secure, scalable environment. Combined with interactive built-in visualizations, these capabilities let scientists run advanced analyses across early discovery and clone selection freeing teams for higher-value work.
About ENPICOM
ENPICOM is a bioinformatics and AI company accelerating biologics discovery and development. Its digital platform unifies data, automates analysis, and integrates AI into scientists' daily workflows, helping life sciences organizations develop better medicines, faster. For more information, visit enpicom.com.